Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 32.65M P/E - EPS this Y 11.90% Ern Qtrly Grth -
Income -10.86M Forward P/E -9.27 EPS next Y 48.10% 50D Avg Chg -3.00%
Sales 49.7M PEG -0.12 EPS past 5Y -28.70% 200D Avg Chg -7.00%
Dividend N/A Price/Book 2.06 EPS next 5Y 30.00% 52W High Chg -42.00%
Recommedations 3.00 Quick Ratio 0.75 Shares Outstanding 16.64M 52W Low Chg 16.00%
Insider Own 19.47% ROA -19.61% Shares Float 12.49M Beta 0.80
Inst Own 19.76% ROE -122.71% Shares Shorted/Prior 321.14K/325.75K Price 2.04
Gross Margin 40.44% Profit Margin -21.85% Avg. Volume 12,787 Target Price -
Oper. Margin -20.89% Earnings Date Nov 12 Volume 8,329 Change -0.49%
About IRIDEX Corporation

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIDEX Corporation News
12/18/24 Iridex Announces Milestone Five-Year Study Confirms the Long-Term Effectiveness and Safety of MicroPulse Transscleral Cyclophotocoagulation for Glaucoma Management
11/19/24 Iridex Comments on Changing Glaucoma Reimbursement Landscape
11/14/24 3 US Penny Stocks With Market Caps Under $50M To Watch
11/13/24 IRIDEX Corp (IRIX) Q3 2024 Earnings Call Highlights: Strategic Moves and Glaucoma Growth Amid ...
11/12/24 Iridex: Q3 Earnings Snapshot
11/12/24 Iridex Reports Third Quarter 2024 Financial Results
11/04/24 Iridex to Report Third Quarter 2024 Financial Results on November 12, 2024
10/09/24 IRIDEX Corp (IRIX) Q2 2024 Earnings Call Highlights: Navigating Growth and Challenges
10/03/24 Iridex Appoints Patrick Mercer as Chief Executive Officer
08/08/24 Iridex (IRIX) Reports Q2 Loss, Misses Revenue Estimates
08/08/24 Iridex: Q2 Earnings Snapshot
08/08/24 Iridex Reports Second Quarter 2024 Financial Results
07/30/24 Iridex to Report Second Quarter 2024 Financial Results on August 8, 2024
05/15/24 Q1 2024 IRIDEX Corp Earnings Call
05/15/24 IRIDEX Corp (IRIX) (Q1 2024) Earnings Call Transcript Highlights: Navigating Challenges with ...
05/14/24 Iridex (IRIX) Reports Q1 Loss, Misses Revenue Estimates
05/14/24 Iridex Reports First Quarter 2024 Financial Results
05/14/24 Even after rising 11% this past week, IRIDEX (NASDAQ:IRIX) shareholders are still down 59% over the past three years
05/08/24 Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
03/27/24 IRIDEX Corporation (NASDAQ:IRIX) Q4 2023 Earnings Call Transcript
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Devi Nandini Director Director May 20 Buy 3.0999 2,000 6,200 10,420 05/23/22
Devi Nandini Director Director Mar 16 Buy 4.20 2,000 8,400 8,420 03/16/22